4.7 Review

Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas

Journal

Publisher

MDPI
DOI: 10.3390/ijms24098324

Keywords

pediatric bone sarcoma; osteosarcoma; Ewing sarcoma; NK cells; adoptive cell therapy; immunotherapy; tumor microenvironment; immune evasion

Ask authors/readers for more resources

Malignant bone tumors, such as Ewing sarcoma and osteosarcoma, are highly aggressive and tend to metastasize, mainly affecting adolescents during rapid growth spurts. Current therapies for pediatric patients with progressive malignant bone sarcomas, despite being aggressive, have poor survival rates and can have long-term effects on bone growth. In recent years, there has been a growing interest in utilizing the immune system, particularly natural killer (NK) cells, for the treatment of cancer. NK-cell immunotherapy has shown promising results in killing pediatric sarcoma cells and has advantages over T-cell adoptive therapy. This review discusses the potential of NK-cell immunotherapy as a new treatment approach for pediatric malignant bone tumors and explores the challenges and future directions in this field.
Malignant bone tumors are aggressive tumors, with a high tendency to metastasize, that are observed most frequently in adolescents during rapid growth spurts. Pediatric patients with malignant bone sarcomas, Ewing sarcoma and osteosarcoma, who present with progressive disease have dire survival rates despite aggressive therapy. These therapies can have long-term effects on bone growth, such as decreased bone mineral density and reduced longitudinal growth. New therapeutic approaches are therefore urgently needed for targeting pediatric malignant bone tumors. Harnessing the power of the immune system against cancer has improved the survival rates dramatically in certain cancer types. Natural killer (NK) cells are a heterogeneous group of innate effector cells that possess numerous antitumor effects, such as cytolysis and cytokine production. Pediatric sarcoma cells have been shown to be especially susceptible to NK-cell-mediated killing. NK-cell adoptive therapy confers numerous advantages over T-cell adoptive therapy, including a good safety profile and a lack of major histocompatibility complex restriction. NK-cell immunotherapy has the potential to be a new therapy for pediatric malignant bone tumors. In this manuscript, we review the general characteristics of osteosarcoma and Ewing sarcoma, discuss the long-term effects of sarcoma treatment on bones, and the barriers to effective immunotherapy in bone sarcomas. We then present the laboratory and clinical studies on NK-cell immunotherapy for pediatric malignant bone tumors. We discuss the various donor sources and NK-cell types, the engineering of NK cells and combinatorial treatment approaches that are being studied to overcome the current challenges in adoptive NK-cell therapy, while suggesting approaches for future studies on NK-cell immunotherapy in pediatric bone tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available